Fluticasone furoate, vilanterol 100/25mcg, 200/25mcg; per inh; dry pwd for oral inh. Increased risk of asthma-related events (death, hospitalizations, intubations) with LABA monotherapy (without ICS).
DUBLIN--(BUSINESS WIRE)--The "Global BREO Ellipta Drugs Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering. The global BREO ellipta drugs market is driven ...
The US Food and Drug Administration (FDA) has approved GlaxoSmithKline's chronic obstructive pulmonary disorder (COPD) drug Breo Ellipta (fluticasone furoate and vilanterol inhalation powder), just ...
WASHINGTON (AP) — A panel of respiratory experts voted Wednesday in favor of approving an experimental inhaler drug from GlaxoSmithKline and Theravance for treating chronic lung disease. A majority of ...
Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) is a prescription inhaler used to treat asthma or COPD in adults. This drug can interact with certain ...
* Today's filing is based upon data generated from comprehensive clinical development programme for FF/VI in asthma * sNDA is seeking approval for two dose regimens, 100/25mcg and 200/25mcg, ...
Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) is a prescription drug used to treat COPD. With COPD, you have lung damage that worsens over time ...
Fluticasone furoate, vilanterol 50/25mcg, 100/25mcg, 200/25mcg; per inh; dry pwd for oral inh. Fluticasone furoate is a synthetic trifluorinated corticosteroid with anti-inflammatory activity. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results